MedTrace Logo

A Study to Evaluate Vitamin B3 Derivative to Treat Mitochondrial Myopathy

NCT05590468 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2026-01-26

No results posted yet for this study

Summary

The purpose of this study is to determine the effects of Nicotinamide Riboside (NR) supplement in adult-onset symptoms of mitochondrial myopathy.

Conditions

  • Mitochondrial Myopathy

Interventions

DRUG

Placebo

Looks exactly like the study drug, but it contains no active ingredient

DIETARY_SUPPLEMENT

Nicotinamide Riboside

Vitamin B3 derivative; a total of 1000 mg/day in a regimen of 500mg every 12 hours by mouth (either fasting or fed)

Sponsors & Collaborators

  • Ralitza Gavrilova

    lead OTHER

Principal Investigators

  • Ralitza H. Gavrilova, MD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-26
Primary Completion
2026-11-30
Completion
2026-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05590468 on ClinicalTrials.gov